nach oben

Inflammation Research

Erschienen in:

01.01.2013 | Original Research Paper

Association of interleukin-1 gene polymorphisms with multiple sclerosis: a meta-analysis

verfasst von: Jian Huang, Zi-Kang Xie, Rong-Bin Lu, Zheng-Fu Xie

Erschienen in: Inflammation Research | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Dysregulated levels of interleukin-1 (IL-1) were observed in patients with multiple sclerosis (MS). Previous studies have provided conflicting evidence implicating the IL-1 gene polymorphisms in MS risk.

Methods

A meta-analysis of 16 case–control studies involving 3,482 cases and 3,528 controls was conducted to evaluate this association.

Results

No association was found between the IL-1α −889 (rs1800587), IL-1α +4,845 (rs17561), IL-1β −511 (rs16944), IL-1β +3,953 (rs1143634), IL-1ra variable number tandem repeat (VNTR) polymorphisms and MS risk. However, in subgroup analyses for the IL-1ra VNTR polymorphism, we found that individuals carrying the 2 allele had a 32 % increased risk for bout-onset MS (relapsing remitting and secondary progressive MS) when compared to the LL homozygotes (OR = 1.32, 95 % CI = 1.06–1.66, P _z = 0.014).

Conclusion

Common variants in the IL-1 region are not associated with MS risk but our data suggest that the IL-1ra VNTR polymorphism might be associated with bout-onset MS subtype.

Matsuda M, Tsukada N, Miyagi K, Yanagisawa N. Increased interleukin-1 production by peripheral blood mononuclear cells in patients with multiple sclerosis. J Neurol Sci. 1991;102:100–4.PubMedCrossRef

Imamura K, Suzumura A, Hayashi F, Marunouchi T. Cytokine production by peripheral blood monocytes/macrophages in multiple sclerosis patients. Acta Neurol Scand. 1993;87:281–5.PubMedCrossRef

Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol. 1995;37:424–35.PubMedCrossRef

Lamkanfi M, Walle LV, Kanneganti TD. Deregulated inflammasome signaling in disease. Immunol Rev. 2011;243:163–73.PubMedCrossRef

Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519–50.PubMedCrossRef

Badovinac V, Mostarica-Stojković M, Dinarello CA, Stosić-Grujicić S. Interleukin-1 receptor antagonist suppresses experimental autoimmune encephalomyelitis (EAE) in rats by influencing the activation and proliferation of encephalitogenic cells. J Neuroimmunol. 1998;85:87–95.PubMedCrossRef

Burger D, Molnarfi N, Weber MS, Brandt KJ, Benkhoucha M, Gruaz L, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci USA. 2009;106:4355–9.PubMedCrossRef

Erbek SS, Yurtcu E, Erbek S, Atac FB, Sahin FI, Cakmak O. Proinflammatory cytokine single nucleotide polymorphisms in nasal polyposis. Arch Otolaryngol Head Neck Surg. 2007;133:705–9.PubMedCrossRef

García-González MA, Aísa MA, Strunk M, Benito R, Piazuelo E, Jiménez P, et al. Relevance of IL-1 and TNF gene polymorphisms on interleukin-1beta and tumor necrosis factor-alpha gastric mucosal production. Hum Immunol. 2009;70:935–45.PubMedCrossRef

10.

Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet. 1993;91:403–4.PubMedCrossRef

11.

Crusius JB, Peña AS, Van Oosten BW, Bioque G, Garcia A, Dijkstra CD, et al. Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis. Lancet. 1995;346:979.PubMedCrossRef

12.

Huang WX, He B, Hillert J. An interleukin 1-receptor-antagonist gene polymorphism is not associated with multiple sclerosis. J Neuroimmunol. 1996;67:143–4.PubMedCrossRef

13.

de la Concha EG, Arroyo R, Crusius JB, Campillo JA, Martin C, Varela de Seijas E, et al. Combined effect of HLA-DRB1*1501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing/remitting multiple sclerosis. J Neuroimmunol. 1997;80:172–8.PubMedCrossRef

14.

Schrijver HM, Crusius JB, Uitdehaag BM, García González MA, Kostense PJ, Polman CH, et al. Association of interleukin-1beta and interleukin-1 receptor antagonist genes with disease severity in MS. Neurology. 1999;52:595–9.PubMedCrossRef

15.

Sciacca FL, Ferri C, Vandenbroeck K, Veglia F, Gobbi C, Martinelli F, et al. Relevance of interleukin 1 receptor antagonist intron 2 polymorphism in Italian MS patients. Neurology. 1999;52:1896–8.PubMedCrossRef

16.

Kantarci OH, Atkinson EJ, Hebrink DD, McMurray CT, Weinshenker BG. Association of two variants in IL-1beta and IL-1 receptor antagonist genes with multiple sclerosis. J Neuroimmunol. 2000;106:220–7.PubMedCrossRef

17.

Ferri C, Sciacca FL, Grimaldi LE, Veglia F, Magnani G, Santuccio G, et al. Lack of association between IL-1A and IL-1B promoter polymorphisms and multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;69:564–5.PubMedCrossRef

18.

Luomala M, Lehtimäki T, Elovaara I, Wang X, Ukkonen M, Mattila K, et al. A study of interleukin-1 cluster genes in susceptibility to and severity of multiple sclerosis. J Neurol Sci. 2001;185:123–7.PubMedCrossRef

19.

Niino M, Kikuchi S, Fukazawa T, Yabe I, Sasaki H, Tashiro K. Genetic polymorphisms of IL-1beta and IL-1 receptor antagonist in association with multiple sclerosis in Japanese patients. J Neuroimmunol. 2001;118:295–9.PubMedCrossRef

20.

Mann CL, Davies MB, Stevenson VL, Leary SM, Boggild MD, Ko Ko C, et al. Interleukin 1 genotypes in multiple sclerosis and relationship to disease severity. J Neuroimmunol. 2002;129:197–204.PubMedCrossRef

21.

Hooper-van Veen T, Schrijver HM, Zwiers A, Crusius JB, Knol DL, Kalkers NF, et al. The interleukin-1 gene family in multiple sclerosis susceptibility and disease course. Mult Scler. 2003;9:535–9.PubMedCrossRef

22.

Dincić E, Zivković M, Stanković A, Obradović D, Alavantić D, Kostić V, et al. Association of polymorphisms in CTLA-4, IL-1ra and IL-1beta genes with multiple sclerosis in Serbian population. J Neuroimmunol. 2006;177:146–50.PubMedCrossRef

23.

Sarial S, Shokrgozar MA, Amirzargar A, Shokri F, Radfar J, Zohrevand P, et al. IL-1, IL-1R and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis. Iran J Allergy Asthma Immunol. 2008;7:37–40.PubMed

24.

Aggelakis K, Zacharaki F, Dardiotis E, Xiromerisiou G, Tsimourtou V, Ralli S, et al. Interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms in Greek multiple sclerosis (MS) patients with bout-onset MS. Neurol Sci. 2010;31:253–7.PubMedCrossRef

25.

Borzani I, Tola MR, Caniatti L, Collins A, De Santis G, Luiselli D, et al. The interleukin-1 cluster gene region is associated with multiple sclerosis in an Italian Caucasian population. Eur J Neurol. 2010;17:930–8.PubMedCrossRef

26.

Mirowska-Guzel D, Gromadzka G, Mach A, Czlonkowski A, Czlonkowska A. Association of IL1A, IL1B, ILRN, IL6, IL10 and TNF-α polymorphisms with risk and clinical course of multiple sclerosis in a Polish population. J Neuroimmunol. 2011;236:87–92.PubMedCrossRef

27.

Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227–31.PubMedCrossRef

28.

McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121–7.PubMedCrossRef

29.

Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58:840–6.PubMedCrossRef

30.

Nikolopoulos GK, Masgala A, Tsiara C, Limitsiou OK, Karnaouri AC, Dimou NL, et al. Cytokine gene polymorphisms in multiple sclerosis: a meta-analysis of 45 studies including 7379 cases and 8131 controls. Eur J Neurol. 2011;18:944–51.PubMedCrossRef

31.

Han B, Eskin E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. Am J Hum Genet. 2011;88:586–98.PubMedCrossRef

32.

Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol. 1998;28:2598–602.PubMedCrossRef

Titel: Association of interleukin-1 gene polymorphisms with multiple sclerosis: a meta-analysis
verfasst von: Jian Huang
Zi-Kang Xie
Rong-Bin Lu
Zheng-Fu Xie
Publikationsdatum: 01.01.2013
Verlag: SP Birkhäuser Verlag Basel
Erschienen in: Inflammation Research / Ausgabe 1/2013
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-012-0556-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Changes in serum cytokine and cortisol levels in normothermic and hypothermic term neonates after perinatal asphyxia

Anti-inflammatory effects of insulin regular and flunixin meglumine on endotoxemia experimentally induced by Escherichia coli serotype O55:B5 in an ovine model

Interleukin-9 release from human kidney grafts and its potential protective role in renal ischemia/reperfusion injury

Journal status and new developments

FcγRIIa requires lipid rafts, but not co-localization into rafts, for effector function